29.08.2023 SARTORIUS AG  DE0007165607

EQS-News: SARTORIUS AG: S&P Global Ratings assigns investment grade rating to Sartorius


EQS-News: SARTORIUS AG / Key word(s): Rating
SARTORIUS AG: S&P Global Ratings assigns investment grade rating to Sartorius (news with additional features)

29.08.2023 / 12:02 CET/CEST
The issuer is solely responsible for the content of this announcement.

Göttingen, Germany, August 29, 2023

S&P Global Ratings assigns investment grade rating to Sartorius
  • Initial rating for Sartorius: Long-term BBB issuer rating with stable outlook
  • S&P Global Ratings highlights Sartorius’ operational strength, financial discipline, and healthy end markets

In its first credit rating, the life science group Sartorius has received a solid investment grade rating. The international rating agency S&P Global Ratings assigned a long-term issuer rating of BBB with a stable outlook. The rating agency particularly acknowledged Sartorius' leading portfolio for life science and biopharma applications, its global reach, strong market fundamentals, and the Sartorius management’s high financial discipline.

"The rating underlines the investment quality of our company and provides a sound basis for the Group's future access to broader capital markets," said Rainer Lehmann, CFO and member of the Executive Board of Sartorius.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.

A profile of Sartorius
The Sartorius Group is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications and vaccines safely, rapidly and economically. The company, based in Goettingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius delivers significant organic growth and regularly expands its portfolio through the acquisition of complementary technologies. In fiscal 2022, the company generated sales revenue of around 4.2 billion euros. At the end of 2022, around 16,000 employees were working for customers around the globe.

Timo Lindemann
Corporate Communications
+49 (0)551 308 4724
[email protected]

Follow Sartorius on X (Twitter) @Sartorius_Group and on LinkedIn.

Additional features:

File: Press Release

29.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Otto-Brenner-Straße 20
37079 Göttingen
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: [email protected]
Internet: www.sartorius.com
ISIN: DE0007165607, DE0007165631
WKN: 716560 , 716563
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1713385

End of News EQS News Service

1713385  29.08.2023 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.404,57 1.566,03 1.826,97 2.335,66 3.449,22 4.174,70 3.395,70
EBITDA1,2 353,20 405,00 495,80 636,70 1.134,26 1.410,40 962,70
EBITDA-Marge3 25,15 25,86 27,14 27,26 32,89 33,78
EBIT1,4 219,36 298,61 335,66 456,11 903,16 1.070,00 503,90
EBIT-Marge5 15,62 19,07 18,37 19,53 26,18 25,63 14,84
Jahresüberschuss1 159,33 197,48 218,74 299,56 426,98 655,40 290,00
Netto-Marge6 11,34 12,61 11,97 12,83 12,38 15,70 8,54
Cashflow1,7 206,51 244,52 377,19 511,53 865,81 734,20 853,60
Ergebnis je Aktie8 2,11 2,56 3,06 4,37 8,08 9,57 4,94
Dividende8 0,51 0,61 0,35 0,70 1,25 1,43 0,45
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: -

Sartorius ST
WKN Kurs in € Einschätzung Börsenwert in Mio. €
716560 275,500 Halten 23.482,37
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
45,16 39,18 1,15 63,35
10,23 24,17 6,92 26,55
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
1,43 0,73 0,26 28.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
18.04.2024 19.07.2024 17.10.2024 16.02.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,43% 6,92% 3,96% -13,91%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SARTORIUS AG  ISIN: DE0007165607 können Sie bei EQS abrufen

Medtech , 716560 , SRT , XETR:SRT